Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

NetEase: Positive Technical Analysis Signals

Tencent/Netease: Both Zeroed in March Game Approval

Tencent/Netease: Game Approval Rotate to Netease in April

Tencent/Netease: Game Approval Accelerates, but Not for Big Names

Tencent/Netease: Netease Tops '23 League Table with Most Games Approved

Tencent/Netease: Game Approval Skewed Towards Netease in '23

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>China announced game approval for the Feb batch. The number of games approved remained at a higher level than 2023.</li>
<li>The pace of China game approval appears to be accelerating, to the same level as pre-tightening.</li>
<li>Netease gets one game approved but we don't see that the acceleration of game approval benefits big names proportionally.</li>
</ul>


China announced game approval for the Feb batch. The number of games approved remained at a higher level than 2023.
The pace of China game approval appears to be accelerating, to the same level as pre-tightening.
Netease gets one game approved but we don't see that the acceleration of game approval benefits big names proportionally.


Tencent/Netease: Approval Rotation to Netease in Feb